文献速递甲状腺疾病

MeIS:基于DNA甲基化的免疫应答特征用于甲状腺结节诊断

MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

研究基于公共简化代表性亚硫酸氢盐测序数据集,识别出15个免疫应答相关基因的DNA甲基化标志物并构建MeIS分类器,在训练集、验证集及两个独立队列中AUC分别为0.96、0.98、0.89和0.90,对细胞学不确定甲状腺结节具有较高灵敏度与特异度,联合BRAF V600E检测可提升诊断性能。

要点

  • MeIS由15个免疫应答相关基因的DNA甲基化标志物组成。
  • 在细胞学不确定结节中,MeIS灵敏度91%、特异度82%(回顾性队列)。
  • MeIS联合BRAF V600E检测灵敏度达98%、特异度82%(回顾性队列)。

核心结论

  • 研究识别的15个标志物可用于改善细胞学不确定甲状腺结节的诊断。

研究设计与样本

  • 研究分析公共简化代表性亚硫酸氢盐测序数据集,构建由15个免疫应答相关基因DNA甲基化标志物组成的MeIS分类器。
  • 在2个独立队列中验证MeIS性能:Z.S.回顾性队列(50例PTC和18例BTN手术剩余样本)和Z.S.术前队列(31例PTC和30例BTN细针穿刺样本)。

主要发现

  • MeIS分类器在训练集、验证集、Z.S.回顾性队列和Z.S.术前队列的AUC分别为0.96、0.98、0.89和0.90。
  • 在细胞学不确定甲状腺结节中,Z.S.回顾性队列中MeIS灵敏度为91%、特异度为82%;Z.S.术前队列中MeIS灵敏度为84%、特异度为74%。
  • MeIS联合BRAF V600E检测在Z.S.回顾性队列和Z.S.术前队列的灵敏度分别为98%和87%,特异度分别为82%和74%。

关键数值与推荐

  • MeIS由15个与免疫应答相关基因相关的DNA甲基化标志物组成。
  • 训练集AUC 0.96,验证集AUC 0.98,Z.S.回顾性队列AUC 0.89,Z.S.术前队列AUC 0.90。
  • 细胞学不确定结节中,Z.S.回顾性队列MeIS灵敏度91%、特异度82%;Z.S.术前队列MeIS灵敏度84%、特异度74%。
  • 联合BRAF V600E检测在Z.S.回顾性队列灵敏度98%、特异度82%;Z.S.术前队列灵敏度87%、特异度74%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Accurately distinguishing between benign thyroid nodules (BTNs) and papillary thyroid cancers (PTCs) with current conventional methods poses a significant challenge. OBJECTIVE: We identify DNA methylation markers of immune response-related genes for distinguishing BTNs and PTCs. METHODS: In this study, we analyzed a public reduced representative bisulfite sequencing dataset and revealed distinct methylation patterns associated with immune signals in PTCs and BTNs. Based on these findings, we developed a diagnostic classifier named the Methylation-based Immune Response Signature (MeIS), which was composed of 15 DNA methylation markers associated with immune response-related genes. We validated MeIS's performance in 2 independent cohorts: Z.S.'s retrospective cohort (50 PTC and 18 BTN surgery-leftover samples) and Z.S.'s preoperative cohort (31 PTC and 30 BTN fine-needle aspiration samples). RESULTS: The MeIS classifier demonstrated significant clinical promise, achieving areas under the curve of 0.96, 0.98, 0.89, and 0.90 in the training set, validation set, Z.S.'s retrospective cohort, and Z.S.'s preoperative cohort, respectively. For the cytologically indeterminate thyroid nodules, in Z.S.'s retrospective cohort, MeIS exhibited a sensitivity of 91% and a specificity of 82%; in Z.S.'s preoperative cohort, MeIS achieved a sensitivity of 84% and a specificity of 74%. Additionally, combining MeIS and BRAF V600E detection improved the detecting performance of cytologically indeterminate thyroid nodules, yielding sensitivities of 98% and 87%, and specificities of 82% and 74% in Z.S.'s retrospective cohort and Z.S.'s preoperative cohort, respectively. CONCLUSION: The 15 markers we identified can be employed to improve the diagnostic of cytologically indeterminate thyroid nodules.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen H, Liu Y, Wang F, et al. MeIS: DNA Methylation-Based Immune Response Signatures for Thyroid Nodule Diagnostics. J Clin Endocrinol Metab. 2024. PMID: 38450587. doi:10.1210/clinem/dgae141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。